Overview:
The revised guidelines are entitled "Integrated Addendum To ICH E6(R1):
Guideline For Good Clinical Practice E6(R2)." The ICH steering committee
comprised of representatives from the pharmaceutical industry and the
regulatory bodies of the United States, Japan, the European Union (EU),
Canada, and Switzerland.
Why should you Attend:
In this webinar we will identify the changes impacting investigators, sites,
Sponsors, CROs: responsibilities and roles and explain the impact of the
revisions on clinical trials conduct and organizational practices.
